CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
Yeshwanter Radhakrishnan, Parikshit Duriseti, Fouad T. Chebib
Kidney Res Clin Pract. 2022;41(4):422-431.   Published online March 29, 2022
DOI: https://doi.org/10.23876/j.krcp.21.309

Excel Download

Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
Kidney Research and Clinical Practice. 2022;41(4):422-431   Crossref logo
Link1 Link2 Link3

Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease: Polycystic Liver Disease
Polycystic Kidney Disease. 2018;171-195   Crossref logo
Link1

Other Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease. 2018;197-206   Crossref logo
Link1

Autosomal Dominant Polycystic Kidney Disease
Diagnostic Pathology: Kidney Diseases. 2016;858-861   Crossref logo
Link1 Link2

Polycystic Kidney Disease, Autosomal Dominant
Imaging in Pediatrics. 2018;194   Crossref logo
Link1 Link2

End-Stage Renal Disease in Patients with Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease. 2018;229-241   Crossref logo
Link1

Polycystic Kidney Disease, Autosomal Dominant
Diagnostic Imaging: Pediatrics. 2017;634-635   Crossref logo
Link1 Link2

Autosomal Dominant Polycystic Kidney Disease
Diagnostic Imaging: Genitourinary. 2016;170-173   Crossref logo
Link1 Link2

Autosomal dominant polycystic kidney disease
Uropathology. 2023;293-295   Crossref logo
Link1 Link2

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Therapeutics and Clinical Risk Management. 2021;Volume 17:649-656   Crossref logo
Link1 Link2